IGI Logo

Zydus Lifesciences is currently trading at Rs 939.55, up by 12.05 points or 1.30% from its previous closing of Rs 927.50 on the BSE.

The scrip opened at Rs 939.55 and has touched a high and low of Rs 941.90 and Rs 931.65 respectively. So far 9851 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1059.00 on 19-Sep-2025 and a 52-week low of Rs 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs 941.90 and Rs 921.00 respectively. The current market cap of the company is Rs 94193.56 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.20% and 6.80% respectively.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg). Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks.

Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh. Verapamil Hydrochloride Extended-Release Tablets had annual sales of $24.5 million in the United States (IQVIA MAT September-2025). The group now has 428 approvals and has so far filed 487 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.